93. Primary biliary cholangitis Clinical trials / Disease details
Clinical trials : 298 / Drugs : 252 - (DrugBank : 59) / Drug target genes : 35 - Drug target pathways : 115
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05293938 (ClinicalTrials.gov) | March 28, 2022 | 4/3/2022 | A Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients | Study Evaluating the Effectiveness of Obeticholic Acid on Hepatic Real-World Outcomes in Patients With Primary Biliary Cholangitis | Primary Biliary Cholangitis | Drug: Obeticholic Acid 5 MG;Drug: Obeticholic Acid 10 MG;Drug: Standard of Care: UDCA | Intercept Pharmaceuticals | Global PBC Study Group;Target RWE;Syneos Health;UK PBC Study Group | Enrolling by invitation | 18 Years | N/A | All | 2350 | United States |